Alector raises $32M for immunotherapy approach to Alzheimer’s and other neurodegenerative disease
Immunotherapy startup Alector just raised $32 million to expand its pipeline of immune system-modulating drugs for neurodegenerative disease. The "hypothesis-driven" company has a bold approach to this family of disease, which has few effective therapies.